Related references
Note: Only part of the references are listed.Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
Thomas K. Eigentler et al.
CANCER TREATMENT REVIEWS (2016)
Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy
Simone M. Goldinger et al.
CLINICAL CANCER RESEARCH (2016)
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
V. R. Belum et al.
EUROPEAN JOURNAL OF CANCER (2016)
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Lars Hofmann et al.
EUROPEAN JOURNAL OF CANCER (2016)
Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma
Namrata Nayar et al.
JOURNAL OF IMMUNOTHERAPY (2016)
Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma
Mariam B. Totonchy et al.
JAMA DERMATOLOGY (2016)
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy
Veronica J. Shi et al.
JAMA DERMATOLOGY (2016)
Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes
Naoko Okiyama et al.
JOURNAL OF AUTOIMMUNITY (2014)
The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies
H. Y. Lee et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory role
P Youngnak-Piboonratanakit et al.
IMMUNOLOGY LETTERS (2004)
Share Paper
